



**Biocure** Technology

# Investor Presentation

July 2018



CSE: CURE | [www.biocuretech.com](http://www.biocuretech.com)

# Forward Looking Statement

## **Forward-Looking Information Not for Distribution; No Offering**

This presentation and the material contained herein are confidential and are not to be disclosed to the public. This presentation is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this presentation.

### Forward-Looking Information

Certain disclosure in this presentation, including statements regarding the potential market for BioCure's products constitute forward-looking statements. In making the forward-looking statements in this release, BioCure has applied certain factors and assumptions that are based on BioCure's current beliefs as well as assumptions made by and information currently available to BioCure, including the assumption that the market for BioCure's product will continue to increase as anticipated. Although BioCure considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this presentation are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, the risk that the market for BioCure product will not increase or continue as anticipated.

Readers are cautioned not to place undue reliance on forward-looking statements. BioCure does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.



# About Us

- Biocure Technology is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products.
  - Pre-clinical trials of a biosimilar candidates of Interferon Beta 1b commenced in 2017 and are expected to be completed in 1Q, 2019.
  - Pre-clinical trials of CAR T-Cell Therapy began in February 2018 and are expected to be completed within 2018.
  - Two additional products are planned for the pre-clinical phase in 2019 & 2020; Ranibizumab and PEG-Filgrastim.
- Biocure's research, development and manufacturing center in Korea is based in one of the jurisdictions where the biopharmaceutical industry is strongly supported by the Government. Korea is one of seven countries in the world equipped with biopharmaceutical infrastructure that can produce biosimilars.



# Company Highlights

- Led by a team of Technical Experts in Korea and highly renowned and recognized in the Korean biopharmaceutical community.
- 16 employees – 4 employees hold PhD degree and 8 employees hold Master degree in biopharmaceutical and/or related fields.
- Our own independent Research & Development facility in Korea (ISO 9001 Acquired)
- Access to GMP facility as needed; Access to fund raising in several jurisdictions including Korea and North America.
- Management has strong and well established networks with Universities, Research Centers and other biopharmaceutical firms in Korea who are collaborating to develop a new pipeline of products.
- Korea is in the top 7 countries in the world in terms of production and manufacturing of Biosimilars.



# Share Structure

- Total Issued & Outstanding Shares: 96,473,301
- Options: 5,105,000
- Warrants 3,790,680
- Fully Diluted: **105,368,981**
- Share Price: \$0.55
- Market Capitalization: \$58 Million
- Major Shareholders: Sang Mok Lee 28%

\*as of June 7, 2018



# Creating Shareholder Value

- Bring Interferon  $\beta$  to the market with a Regulatory & Clinical submission to EMA and FDA by the end of 2020
- Initiate IRB and ANVISA approval to explore new partnerships for FMD Vaccine Program in Brazil and other South American Countries in 2019
- Obtain preclinical trial approval on CAR-T Cell by the end of 2018 and proceed to clinical trial in 2Q 2019
- Start preclinical trials for Ranibizumab in 2019 and PEG-Filgristim in 2020.
- Management has a mandate to make treatment affordable and available to many patients whom previously did not have the means to receive.



# Company Milestones

Classification	Key Content
Aug. 2005	Company founded (Paid-in capital of USD 50,000)
Nov. 2006	Awarded the national export tower of USD 1 million
Dec. 2007	Achieved export of USD 4.5 million
Jan. 2015	Agreed with Biocurepharm(Korea)-Atabay(Turkey) for joint development of Ranibizumab
Feb. 2016	Contracted IPO in Canada stock market with Columbia Capital Inc.
Oct. 2016	Contracted joint venture for FMD Vaccine production with Pharos Vaccine, Korea
Oct. 2016	On going process, Bio-similar and a FMD Vaccine joint factory project with ORNA, Turkey
Oct. 2017	Launched RCHG(Recure Cell Hair Growpac)
Nov. 2017	Listed in the Canada Stock Exchange (CSE)
Dec.2017	Pre-clinical trial of Interferon $\beta$
Feb.2018	Pre-clinical trial of CAR-T cell immunotherapy





# Biosimilar Industry

Biosimilars have become a hot topic over the past few years and their development has been gaining significant momentum.




# Biosimilar Industry



## THE NEED FOR U.S. BIOSIMILARS



Generic drugs were introduced 30 years ago, saving billions of dollars, improving patient access and changing healthcare forever. Biosimilars now hold the same potential.



**\$250 BILLION** COULD BE SAVED IN THE NEXT DECADE IF THESE 11 BIOSIMILARS ARE APPROVED



### WE KNOW BIOSIMILARS CAN DRIVE COST DOWN SAFELY



### WE NEED A CLEAR PATH FORWARD IN THE U.S.

- FDA APPROVAL**
- LAW**  
NO UNNECESSARY HURDLES IN STATE SUBSTITUTION LAWS
- HELLO**  
EASY-TO-USE NAMING STRUCTURE


For the latest Express Scripts research, visit: <http://Lab.Express-Scripts.com>.

© 2014 Express Scripts Holding Company. All Rights Reserved. ES-1400000



## Biosimilars Markets Are Well Established

The market estimates are based on current sales and highly underestimate the future markets, yet biosimilars present one of best business models, as the generic pharma market is steadily declining.



Source: *visiongain 2017*





# Biocure's Biosimilar Products

# What is a Biosimilar?


Health Canada defines a biosimilar biological drug, or biosimilar, as a drug demonstrated to be highly similar to a biological drug that was already authorized for sales (known as the “reference biological drug”)

There are no clinically meaningful differences in terms of **safety** and **efficacy** between a biosimilar and a reference biological drug

Biosimilars have the potential to improve the lives of patients by providing additional treatment options, which can expand access and generate savings and efficiencies for health care systems. This will bring new hope to patients who were unable to afford big pharma drugs previously. We believe all people deserve the best medications available and no one should be denied proper healthcare due to economic conditions.



# Company Roadmap (To be updated)



# Interferon $\beta$ -1b

## A Treatment for Multiple Sclerosis

### Development Status

- Pre-clinical trial is in progress after completed the preparation for mass production
- Begin clinical trial in 3Q 2019.  
Expected to take 18 - 24 months

### ➤ Market Entry Strategy

- Launch in the Middle Eastern, North African and Brazil markets
- Set up the Joint Venture in Turkey and Brazil

### ➤ Current Market Conditions:

- The Multiple Sclerosis Market size in 2017 was approximately USD 9 billion
- There are currently only three main competitors in the world
- Patients are predominantly in developed countries such as America and Western Europe, as well as in the Middle East, North Africa and Eastern Europe.



# CAR-T Cell Therapy

## A Treatment for Acute lymphoblastic leukemia (ALL)

### ➤ Development Status

- pre-clinical and clinical designs of 2<sup>nd</sup> generation CAR-T cell, standard protocol for conditioning and infusion, better control of complications and combination with other therapeutic options.
- Pre-clinical start early of 2018 and clinical study will start in 2Q 2019.


### ➤ Current Market Conditions:

- According to the NIH, more than 340,000 Americans suffered from leukemia in 2015.
- In 2017 Global CAR-T Cell therapeutics market was \$72M. Predicting an annual growth rate 53.9% in the next 11 years (2017~2028)
- CAR-T Cell therapeutics is expected to generate huge revenue opportunities in commercial



# CAR-T Cell Therapy

Global CAR-T Cell immunotherapy market status and forecast (2017-2028, million dollars)



Coherent Market Insights, CAR-T Cell therapy market(2017.2)





## Treatment of Neutropenia

**Neutropenia** is an abnormally low level of neutrophils. Neutrophils are a common type of white blood cell important to fighting off infections - particularly those caused by bacteria.

Filgrastim (G-CSF, Granulocyte Colony Stimulating Factor) is the 1<sup>st</sup> generation, an anti-cancer treatment which plays an important role in the recovery of the cancer patient's immunity

### ➤ Current Market Conditions

- Amgen created a market of USD 6 billion or more by selling first generation drug called Neupogen, the first generation.

- Sales and proportion of Neublasta (PEG-GCSF, 2<sup>nd</sup> generation) are increasing in total market for GCSF.
- Multiple number of companies produce the first generation Filgrastim

### ➤ Status of Current Development

- Secured production technology of the first generation of Filgrastim
- We will produce the 2<sup>nd</sup> generation Filgrastim.
- Pre-clinical and clinical period is expected about 30 months

### ➤ Market Entry Strategy

- Plan to launch in Middle East, Eastern Europe, Turkey, Thailand and Malaysia through oversea partners



# Ranibizumab

**Treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.**

## ➤ Development Status

- It can be produced by recombinant *E. coli*
- Pre-clinical trial can start in 2019.

## ➤ Market Entry Strategy


- Launch in Korean market first and export to emerging countries

## ➤ Current Market Conditions

- Market entered with the name "Lucentis" by Novartis
- High priced biopharmaceuticals of USD 1200 for 3mg/vial

- High demand getting an aging society, it can be one of blockbuster biopharmaceuticals
- Manufacturing cost is extremely low compare to selling price

Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis, and the patent expired in 2017



- The revenue of Lucentis is estimated to be about USD 1.8 billion in 2017.



# In Summary

BioCure Technology intends to become a leader in the Biosimilar space. With the recent Canadian listing, and the impending OTCQB listing, Management can now expand and further build its relationships in North America.

The Company is well positioned for growth in 2018 and intends on creating shareholder value by:

- Focusing on moving Interferon  $\beta$ , CAR T cell program to the approval stage
- Building valuable partnerships
- Establishing a clearly defined regulatory and clinical pathway world wide
- Adding to our exceptional Management Team and Advisory Board



# Board of Directors & Management

## **Sang Mok Lee, CEO & President, Director**

Dr. Lee has been a President and CEO since the inception in 2005. Dr. Lee holds a PhD in microbiology from Busan National University in Korea and is currently an adjunct professor in microbiology at Chungnam National University. Dr. Lee is a committee member for the hi-tech medical complex city in Daejeon, Korea and a committee member of KOFST (the Korean Federation of Science and Technology Societies).

## **Konstantin Lichtenwald, CFO, Director**

Mr. Lichtenwald has over ten years of finance and accounting experience, including corporate compliance, accounting and financial management and IPO, RTO services. Mr. Lichtenwald offers extensive knowledge and know-how for companies in two key financial jurisdictions, North America and German speaking parts of Europe. His accounting, financial skills offer a multi-faceted hands on approach to strategic management and problem solving. Mr. Lichtenwald earned his bachelor of business administration degree from Pforzheim University, Germany, and holds the professional designation of Chartered Professional Accountant (CPA, CGA) and Chartered Certified Accountant (ACCA), where he is a member of Chartered Professional Accountants of B.C. and Canada as well as a member of the Association of Chartered Certified Accountants of United Kingdom.



# Board of Directors & Management

## **Collin (Sang Goo) Kim, Director**

Mr. Kim holds a bachelor degree of business administration from Korea University, Seoul, Korea. Mr. Kim came to Vancouver, Canada in 2006 after working for Hanwha Corp., one of Korean business conglomerates for 16 years, where he was dedicated to International trading business for various industrial products. He has been working as a Vice President for Columbia Capital since 2008 and a director of ArcPacific Resources Corp., a public Canadian junior exploration company, since 2015. He is imperative in the communication between Korean management and Canadian management cross the border with his vast knowledge and work experience.

## **Marco Nonni, Director**

Mr. Nonni graduated from Santa Clara University with a Bachelor of Science Degree in 1989 and has over 16 years of experience with Biotech and top ten Pharmaceuticals companies in business development activities in the life science industry. He will be focusing on building key partnership for the advancement of the company. Throughout his career, he has have provided leadership and management within Clinical Development for medical and scientific support to products within assigned therapy areas such as Oncology, Cardiovascular, Metabolic, and Rare Genetic Disorders.

**The Company also has a very strong Advisory Board comprised of Medical Professionals that have key industry contacts and alliances. For their full Bio's and Summary of expertise please see our website.**





# Biocure Technology

## THANK YOU

Contact us below:

[admin@biocuretech.com](mailto:admin@biocuretech.com)

(604) 609-7146

#300, 1055 West Hastings Street

Vancouver, BC V6E 2S9

CSE: CURE | [www.biocuretech.com](http://www.biocuretech.com)

